ImmunoGen Antibody-Drug Conjugate Faces Delay After Study Split
Following FDA Guidance
Executive Summary
Top-line results from the firm’s pivotal trial of pivekimab sunirine in a rare cancer indication have been delayed for two more years as the firm shifts focus to a specific subpopulation.